#scynexis

PharmaShots Weekly Snapshots (October 18 – 22, 2021)

LEO Reports 16-week Results of Tralokinumab in P-III ECZTRA 6 Trial for the Treatment of Moderate-to-Severe Atopic Dermatitis Published: 22 Oct, 2021 | Tags: LEO, Tralokinumab, P-III, ECZTRA 6 Trial, Atopic Dermatitis Marinomed Biotech Signs a License Agreement with Luoxin to Commercialize Budesolv (budesonide nasal spray) in Greater China Published: 22 Oct, 2021 | Tags: …

PharmaShots Weekly Snapshots (October 18 – 22, 2021) Read More »

Scynexis Reports Results of Ibrexafungerp in P-III VANISH-303 Trial for Treatment of Vaginal Yeast Infection

Shots: The P-III VANISH-303 evaluates ibrexafungerp vs PBO in patients with VVC & P-II DOVE studies assess ibrexafungerp vs fluconazole for the same indication. The results were published in America’s Clinical Infectious Diseases In the P-III study, the therapy was superior in completely resolving signs & symptoms of VVC @10 Day (50.5% vs 28.6%); superior …

Scynexis Reports Results of Ibrexafungerp in P-III VANISH-303 Trial for Treatment of Vaginal Yeast Infection Read More »

Insights+: The US FDA New Drug Approvals in June 2021

The US FDA has approved 6 NDAs and 2 BLAs in 2021, leading to treatments for patients and advances in the health care industry The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 37 novel products in 2021 Additionally, last year in 2020, the US FDA …

Insights+: The US FDA New Drug Approvals in June 2021 Read More »

Scynexis bids to end novel antifungal drought, filing ibrexafungerp in US

Scynexis has filed for FDA approval of its novel drug ibrexafungerp which – if approved – would be the first broad-spectrum antifungal to reach the US market for vaginal yeast infections in more than two decades. The Jersey City, US-based biotech has submitted ibrexafungerp (SCY-078) on schedule as a treatment for the vulvovaginal candidiasis (VVC), …

Scynexis bids to end novel antifungal drought, filing ibrexafungerp in US Read More »